Get the Stockscreener App
31.70
1.61%
-0.52
Pre-market:
31.49
-0.21
-0.66%
Legend Biotech Corp Adr stock is traded at $31.70, with a volume of 1.91M.
It is down -1.61% in the last 24 hours and down -5.29% over the past month.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
See More
Previous Close:
$32.22
Open:
$32.09
24h Volume:
1.91M
Relative Volume:
1.60
Market Cap:
$5.85B
Revenue:
$520.18M
Net Income/Loss:
$-348.13M
P/E Ratio:
-16.51
EPS:
-1.92
Net Cash Flow:
$-176.18M
1W Performance:
-1.12%
1M Performance:
-5.29%
6M Performance:
+1.34%
1Y Performance:
-36.93%
1-Day Range:
$31.18
$32.44
1-Week Range:
$31.18
$33.21
52-Week Range:
$27.34
$51.77
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Name
Legend Biotech Corp Adr
Sector
Industry
Phone
-
Address
-
Compare LEGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
31.70 | 5.95B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Jun-17-24 | Initiated | Truist | Buy |
| May-24-24 | Reiterated | H.C. Wainwright | Buy |
| May-23-24 | Initiated | Deutsche Bank | Buy |
| Apr-17-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Apr-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | Raymond James | Outperform |
| Dec-19-23 | Initiated | Scotiabank | Sector Perform |
| Nov-06-23 | Initiated | Goldman | Buy |
| May-25-23 | Initiated | William Blair | Mkt Perform |
| May-22-23 | Initiated | Daiwa Securities | Buy |
| Mar-29-23 | Initiated | H.C. Wainwright | Buy |
| Mar-24-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-22 | Initiated | UBS | Buy |
| Nov-02-22 | Initiated | Evercore ISI | Outperform |
| Nov-01-22 | Initiated | Cowen | Outperform |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Mar-15-22 | Initiated | Barclays | Overweight |
| Jan-31-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-21-21 | Initiated | Piper Sandler | Overweight |
| May-18-21 | Initiated | BTIG Research | Buy |
| Jul-01-20 | Initiated | JP Morgan | Overweight |
| Jul-01-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Morgan Stanley | Overweight |
View All
Legend Biotech Corp Adr Stock (LEGN) Latest News
US FDA adds label warning to J&J’s and Legend Biotech’s cancer therapy By Reuters - Investing.com
JPMorgan Chase & Co. Cuts Legend Biotech (NASDAQ:LEGN) Price Target to $76.00 - Defense World
Mirae Asset Global Investments Co. Ltd. Has $530,000 Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
US FDA adds boxed warning to J&J, Legend Biotech’s cancer therapy By Reuters - Investing.com
Legend Biotech (NASDAQ:LEGN) Research Coverage Started at Cantor Fitzgerald - Defense World
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Public Employees Retirement System of Ohio - Defense World
GAMMA Investing LLC Has $30,000 Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Matthews International Capital Management LLC Has $45.89 Million Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Voya Investment Management LLC Takes Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Harbor Capital Advisors Inc. Grows Stock Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Rhumbline Advisers Buys 391 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Advisors Asset Management Inc. Has $673,000 Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics - MSN
Alliancebernstein L.P. Purchases 32,101 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock rating reiterated at Outperform by RBC Capital - Investing.com
Legend Biotech Corporation Sponsored ADR $LEGN Stake Decreased by Cinctive Capital Management LP - MarketBeat
Nomura Holdings Inc. Purchases New Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech at Morgan Stanley Conference: CARVYKTI’s Global Impact - Investing.com
Legend Biotech (NASDAQ:LEGN) Shares Up 5.4%Here's Why - MarketBeat
Legend Biotech Mulling 2nd Listing in HK, Singapore, or London: Wire - AASTOCKS.com
Northern Trust Corp Has $9.73 Million Stake in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Rexel (OTCMKTS:RXLSF) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Cantor Fitzgerald Expects Weaker Earnings for Legend Biotech - MarketBeat
Legend Biotech’s SWOT analysis: carvykti success drives stock potential amid challenges - Investing.com India
Nuveen LLC Purchases Shares of 170,186 Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Brokers Issue Forecasts for Legend Biotech FY2025 Earnings - Defense World
Price T Rowe Associates Inc. MD Sells 78,302 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech (NASDAQ:LEGN) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Resolute Capital Asset Partners LLC Buys New Stake in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
170,186 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Nuveen LLC - Defense World
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $78.00 at JPMorgan Chase & Co. - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives $72.38 Average PT from Brokerages - Defense World
PNC Financial Services Group Inc. Buys 3,238 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Swiss National Bank Has $5.53 Million Holdings in National Storage Affiliates Trust $NSA - Defense World
Occidental Petroleum (NYSE:OXY) & Berry (NASDAQ:BRY) Critical Survey - Defense World
Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Boosted by Swiss National Bank - Defense World
US Bancorp DE Lowers Position in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Contrasting Hillenbrand (NYSE:HI) and IperionX (NASDAQ:IPX) - Defense World
Legend Biotech names Carlos Santos as new CFO - Investing.com
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition - Investing.com
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition By Investing.com - Investing.com South Africa
Company News for Aug 12, 2025 - NewsBreak: Local News & Alerts
Legend Biotech (NASDAQ:LEGN) Price Target Raised to $83.00 at Morgan Stanley - Defense World
Legend Biotech (NASDAQ:LEGN) Receives Outperform Rating from Royal Bank Of Canada - Defense World
Legend Biotech stock price target raised to $77 by RBC Capital - Investing.com South Africa
Legend Biotech Corp Adr Stock (LEGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):